Sanofi SA
NASDAQ:SNY

  • LAST PRICE
    57.4700
  • TODAY'S CHANGE (%)
    0.5600 (0.9840%)
  • Bid / Lots
    56.6700/ 1
  • Ask / Lots
    58.2000/ 1
  • Open / Previous Close
    57.2800 / 56.9100
  • Day Range
    57.0700
    57.5300
  • 52 Week Range
    42.6300
    58.9700
  • Volume
    1,354,992

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Sep 16, 2024

      Show headlines and story abstract

    • 9:01AM ET on Monday Sep 16, 2024 by MT Newswires
      Companies Mentioned: SNY, AZN
      09:01 AM EDT, 09/16/2024 (MT Newswires) -- Sanofi (SNY) said Monday it is shipping Beyfortus in the US to help protect eligible babies ahead of the respiratory syncytial virus disease season. The company said 50 mg and 100 mg injection doses are bei...

    • 8:00AM ET on Monday Sep 16, 2024 by Dow Jones
      Companies Mentioned: SNY

      the availability or commercial potential of the product, the fact that product may not be commercially successful, the uncertainties inherent in research and development, including future clinical data and analysis of existing clinical data relating to the product, including post marketing, unexpected safety, quality or manufacturing issues, competition in general, risks associated with intellectual property and any related future litigation and the ultimate outcome of such litigation, and volatile economic and market conditions, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the financial condition of any one of them, as well as on our employees and on the global economy as a whole. The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

  • Sep 13, 2024

      Show headlines and story abstract

    • 1:49PM ET on Friday Sep 13, 2024 by MT Newswires
      Companies Mentioned: REGN, SNY
      01:49 PM EDT, 09/13/2024 (MT Newswires) -- Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) said Friday that the US Food and Drug Administration approved Dupixent as a supplementary maintenance treatment for inadequately controlled chronic rhinosin...

    • 12:49PM ET on Friday Sep 13, 2024 by Dow Jones
      Companies Mentioned: REGN, SNY

      By Connor Hart

      Regeneron Pharmaceuticals and Sanofi have received Food and Drug Administration approval for their treatment of an inflammatory condition that affects the sinuses and nasal passages in adolescents, the companies said.

    • 12:15PM ET on Friday Sep 13, 2024 by Dow Jones
      Companies Mentioned: REGN, SNY

      administrative governmental authorities which may delay or restrict Regeneron's ability to continue to develop or commercialize Regeneron's Products and Regeneron's Product Candidates; ongoing regulatory obligations and oversight impacting Regeneron's Products, research and clinical programs, and business, including those relating to patient privacy; the availability and extent of reimbursement of Regeneron's Products from third-party payers, including private payer healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; coverage and reimbursement determinations by such payers and new policies and procedures adopted by such payers; competing drugs and product candidates that may be superior to, or more cost effective than, Regeneron's Products and Regeneron's Product Candidates; the extent to which the results from the research and development programs conducted by Regeneron and/or its collaborators or licensees may be replicated in other studies and/or lead to advancement of product candidates to clinical trials, therapeutic applications, or regulatory approval; unanticipated expenses; the costs of developing, producing, and selling products; the ability of Regeneron to meet any of its financial projections or guidance and changes to the assumptions underlying those projections or guidance; the potential for any license, collaboration, or supply agreement, including Regeneron's agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable) to be cancelled or terminated; the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on Regeneron's business; and risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings relating to EYLEA(R) (aflibercept) Injection), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including the pending civil proceedings initiated or joined by the U.S. Department of Justice and the U.S. Attorney's Office for the District of Massachusetts), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on Regeneron's business, prospects, operating results, and financial condition. A more complete description of these and other material risks can be found in Regeneron's filings with the U.S. Securities and Exchange Commission, including its Form 10-K for the year ended December 31, 2023 and its Form 10-Q for the quarterly period ended June 30, 2024. Any forward-looking statements are made based on management's current beliefs and judgment, and the reader is cautioned not to rely on any forward-looking statements made by Regeneron. Regeneron does not undertake any obligation to update (publicly or otherwise) any forward-looking statement, including without limitation any financial projection or guidance, whether as a result of new information, future events, or otherwise.

Peers Headlines